Perrigo (PRGO) Q2 EPS Rises 7.5%

Perrigo (PRGO) reported mixed Q2 FY2025 results, with adjusted EPS of $0.57 missing analyst estimates despite a 7.5% year-over-year increase, and GAAP revenue declining 0.9% to $1.06 billion, also below forecasts. While full-year adjusted EPS guidance was reaffirmed, the company now expects FY2025 sales growth to be at the lower end of prior ranges due to soft consumption in categories like Digestive Health and Oral Care, and operational challenges in infant formula. Strategic initiatives like Project Energize cost savings and the announced Dermacosmetics divestiture, aimed at debt reduction, are anticipated to support performance, with earnings expected to be weighted towards the second half of the fiscal year.

Analysis

Perrigo's Q2 FY2025 results revealed operational challenges, with both revenue and earnings falling short of analyst expectations. The company reported adjusted EPS of $0.57, missing the $0.59 consensus, and GAAP revenue of $1.06 billion, a decline of 0.9% year-over-year. The top-line weakness was driven by nearly flat organic sales (-0.1%), reflecting soft consumption and lost distribution in key U.S. categories like Digestive Health (-12.9%) and Oral Care (-18.1%), compounded by production issues in infant formula. This softness directly impacted profitability, with adjusted gross margin contracting by 250 basis points and adjusted operating income falling 2.9%. Although adjusted EPS grew 7.5%, this was primarily attributable to lower interest expenses rather than core operational strength. While management reaffirmed its full-year EPS guidance of $2.90-$3.10, it conceded that sales growth would likely land at the low end of its prior range. Achieving the earnings target is now heavily reliant on a second-half recovery, cost-saving initiatives like Project Energize, and the successful execution of strategic moves such as the sale of its Dermacosmetics business to reduce leverage.

Key Decisions for Investors

• Given the revenue miss and lowered sales outlook, investors should recognize the increased execution risk in Perrigo meeting its reaffirmed full-year EPS guidance, which is now highly dependent on a significant second-half performance.
• Monitor key operational metrics closely, specifically the sales trends in the underperforming U.S. Oral Care and Digestive Health categories and any signs of stabilization in infant formula production.
• The announced divestiture of the Dermacosmetics business is a critical catalyst; track its completion and the subsequent use of proceeds for debt reduction, as improving the balance sheet is a stated priority.
• While the Americas segment struggles, consider the relative strength and margin expansion in the International division, as its continued performance may provide a partial buffer against domestic weakness.